
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Researchers activate chemotherapeutics by ultrasound
Chemotherapeutic treatments produce strong side effects. A new drug complex that accumulates in the tumour tissue and is only activated there by...

eXmoor Pharma Ltd raises US$35m
The financing of eXmoor Pharma Ltd. was led by new investor Kineticos Ventures and existing investor MVM Partners to help launching...

Phialogics AG bags pre-seed financing
Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...

Confo Therapeutics and Lilly partner to advance CFTX-1554
Under the agreement, Confo Therapeutics BV got a $40m upfront and milestone payments totalling $590m for licencing its clinical stage angiotensin II...

Genmab and argenx combine antibody know-how
Genmab A/S and argenx will start their collaboration jointly launching two antibody programmes in immunology and oncology with the...

5 Alarm Bio Ltd raises £500K in seed round
Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, as well as other angel investors participated in Five Alarm Bio’s (FAB) seed round with...